Protara Therapeutics, Inc. (TARA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Protara Therapeutics, Inc. (TARA)

Company Performance

Current Price

as of Oct 16, 2024

$1.86

P/E Ratio

N/A

Market Cap

$38.37M

Description

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Metrics

Overview

HQNew York, NY
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerTARA
Price$1.86+3.91%

Trading Information

Market Cap$38.37M
Float89.26%
Average Daily Volume (1m)117,468
Average Daily Volume (3m)146,673
EPS-$3.19

Company

RevenueN/A
Rev Growth (1yr)N/A
Net Income-$9.51M
Gross MarginN/A
EBITDA MarginN/A
EBITDA-$10.58M

EV-$40.43M
EV/RevenueN/A
P/EN/A
P/SN/A
P/B0.23

Documents

Factset Street Account

Protara Therapeutics reports Q3 EPS ($0.87) vs FactSet ($0.98) [4 est, ($1.12)-(0.66)] ($1.21, 0.00) (2023-11-03T12:04:13Z)

Protara Therapeutics presents new Phase 1a ADVANCED-1 trial data of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology ($1.49, 0.00) (2023-11-30T13:36:05Z)

Protara Therapeutics announces dosing of first patient in Phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with lymphatic malformations ($1.42, 0.00) (2023-10-23T12:02:33Z)